Free Trial
→ A grave, grave error. (From Porter & Company) (Ad) Free NUVB Stock Alerts

Nuvation Bio (NUVB) Financials

Nuvation Bio logo
$2.20 -0.11 (-4.76%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$2.22 +0.02 (+1.09%)
As of 07/11/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Nuvation Bio

Annual Income Statements for Nuvation Bio

This table shows Nuvation Bio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -42 -87 -104 -76 -568
Consolidated Net Income / (Loss)		 -42 -87 -104 -76 -568
Net Income / (Loss) Continuing Operations		 -42 -87 -104 -76 -568
Total Pre-Tax Income 		-42 -87 -104 -76 -568
Total Operating Income		 -44 -93 -120 -100 -593
Total Gross Profit		 0.00 0.00 0.00 0.00 0.80
Total Revenue		 0.00 0.00 0.00 0.00 7.87
Operating Revenue		 - - - 0.00 7.87
Total Cost of Revenue		 0.00 0.00 0.00 0.00 7.08
Operating Cost of Revenue		 - - - 0.00 7.08
Total Operating Expenses		 44 93 120 100 593
Selling, General & Admin Expense		 11 24 32 29 69
Research & Development Expense		 33 69 88 71 524
Total Other Income / (Expense), net		 1.89 6.47 16 24 25
Interest Expense		 - - - 0.00 0.34
Interest & Investment Income		 2.16 2.88 6.22 25 27
Other Income / (Expense), net		 -0.27 3.59 9.32 -0.45 -1.91
Income Tax Expense		 0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share		 ($0.43) ($0.44) ($0.48) ($0.35) ($2.11)
Weighted Average Basic Shares Outstanding		 97.53M 197.89M 216.72M 218.88M 268.77M
Diluted Earnings per Share		 ($0.43) ($0.44) ($0.48) ($0.35) ($2.11)
Weighted Average Diluted Shares Outstanding		 97.53M 197.89M 216.72M 218.88M 268.77M
Weighted Average Basic & Diluted Shares Outstanding		 97.53M 219.06M 218.80M 219.05M 338.68M

Quarterly Income Statements for Nuvation Bio

This table shows Nuvation Bio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -27 -21 -22 -21 -19 -15 -15 -462 -39 -52 -53
Consolidated Net Income / (Loss)		 -27 -21 -22 -21 -20 -14 -15 -462 -41 -49 -53
Net Income / (Loss) Continuing Operations		 -27 -21 -22 -21 -20 -14 -15 -462 -41 -49 -53
Total Pre-Tax Income 		-27 -21 -22 -21 -20 -14 -15 -462 -41 -49 -53
Total Operating Income		 -29 -24 -27 -26 -26 -21 -20 -470 -48 -54 -59
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.09 -0.79 1.50 0.99
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 1.44 0.73 5.71 3.08
Operating Revenue		 - - - - 0.00 - 0.00 1.44 0.73 - 3.08
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 1.35 1.52 4.22 2.09
Operating Cost of Revenue		 - - - 0.00 0.00 - 0.00 1.35 1.52 - 2.09
Total Operating Expenses		 29 24 27 26 26 21 20 471 47 55 60
Selling, General & Admin Expense		 8.04 7.46 7.73 7.54 7.78 5.48 7.36 16 20 26 35
Research & Development Expense		 21 17 19 19 19 15 13 454 28 29 25
Total Other Income / (Expense), net		 2.14 3.49 4.80 5.49 6.69 7.04 5.41 7.89 6.89 4.50 5.77
Interest Expense		 - - - 0.00 0.00 - 0.00 0.13 0.12 - 0.05
Interest & Investment Income		 1.94 3.39 5.08 6.09 6.52 6.93 7.13 7.14 6.73 6.07 5.32
Other Income / (Expense), net		 0.20 0.10 -0.09 -0.50 0.16 -0.02 -1.72 1.14 0.30 -1.62 0.50
Income Tax Expense		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Basic Earnings per Share		 ($0.12) ($0.10) ($0.10) ($0.09) ($0.09) ($0.07) ($0.07) ($1.89) ($0.15) - ($0.16)
Weighted Average Basic Shares Outstanding		 218.30M 216.72M 218.74M 218.85M 218.94M 218.88M 219.05M 244.74M 273.57M 268.77M 338.61M
Diluted Earnings per Share		 ($0.12) ($0.10) ($0.10) ($0.09) ($0.09) ($0.07) ($0.07) ($1.89) ($0.15) - ($0.16)
Weighted Average Diluted Shares Outstanding		 218.30M 216.72M 218.74M 218.85M 218.94M 218.88M 219.05M 244.74M 273.57M 268.77M 338.61M
Weighted Average Basic & Diluted Shares Outstanding		 218.39M 218.80M 218.80M 218.94M 218.94M 219.05M 247.17M 249.25M 336.57M 338.68M 340.26M

Annual Cash Flow Statements for Nuvation Bio

This table details how cash moves in and out of Nuvation Bio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -108 103 -31 -58 -6.93
Net Cash From Operating Activities		 -37 -68 -96 -68 -130
Net Cash From Continuing Operating Activities		 -173 -63 -96 -68 -130
Net Income / (Loss) Continuing Operations		 -42 -87 -104 -76 -568
Consolidated Net Income / (Loss)		 -42 -87 -104 -76 -568
Depreciation Expense		 0.10 0.18 0.20 0.22 0.68
Amortization Expense		 - 4.59 3.67 -12 -9.00
Non-Cash Adjustments To Reconcile Net Income		 -134 7.14 8.51 18 458
Changes in Operating Assets and Liabilities, net		 2.37 12 -4.28 1.76 -13
Net Cash From Investing Activities		 -70 -455 63 8.92 123
Net Cash From Continuing Investing Activities		 -70 -455 63 8.92 123
Purchase of Property, Plant & Equipment		 -0.15 -0.28 -0.37 -0.07 -0.16
Acquisitions		 - - - 0.00 -7.43
Purchase of Investments		 -143 -609 -520 -703 -340
Sale of Property, Plant & Equipment		 - 0.00 0.01 0.01 0.00
Divestitures		 - - - 0.00 20
Sale and/or Maturity of Investments		 73 155 584 712 450
Net Cash From Financing Activities		 133 626 1.33 0.63 0.33
Net Cash From Continuing Financing Activities		 136 626 1.33 0.63 0.33
Repayment of Debt		 - - - 0.00 -17
Issuance of Debt		 136 - - 0.00 13
Issuance of Common Equity		 0.00 0.31 0.39 0.25 0.43
Other Financing Activities, net		 0.00 625 0.94 0.38 4.46
Effect of Exchange Rate Changes		 - - - 0.00 0.45
Cash Interest Paid		 - - - 0.00 0.34
Cash Income Taxes Paid		 - - - 0.00 0.37

Quarterly Cash Flow Statements for Nuvation Bio

This table details how cash moves in and out of Nuvation Bio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 36 -38 -71 20 -26 18 -8.14 -0.23 -4.25 5.69 12
Net Cash From Operating Activities		 -28 -16 -19 -17 -16 -15 -16 -37 -31 -46 -43
Net Cash From Continuing Operating Activities		 -28 -16 -19 -17 -16 -15 -16 -37 -31 -46 -43
Net Income / (Loss) Continuing Operations		 -27 -21 -22 -21 -20 -14 -15 -462 -41 -49 -53
Consolidated Net Income / (Loss)		 -27 -21 -22 -21 -20 -14 -15 -462 -41 -49 -53
Depreciation Expense		 0.06 0.05 0.06 0.06 0.06 0.06 0.06 0.24 0.16 0.22 0.31
Amortization Expense		 0.59 -0.43 -2.15 -3.22 -3.43 -3.26 -2.82 -2.42 -2.10 -1.65 -1.47
Non-Cash Adjustments To Reconcile Net Income		 3.18 4.74 5.00 5.35 4.80 2.73 5.88 434 6.85 12 7.53
Changes in Operating Assets and Liabilities, net		 -4.72 0.32 -0.51 0.97 2.07 -0.77 -4.03 -6.51 5.22 -7.31 4.24
Net Cash From Investing Activities		 106 -22 -52 37 -9.59 33 7.54 34 29 52 54
Net Cash From Continuing Investing Activities		 64 -22 -52 37 -9.59 33 7.54 34 29 52 54
Purchase of Property, Plant & Equipment		 -0.10 -0.07 -0.01 -0.02 -0.02 -0.01 -0.03 - -0.15 0.01 -0.07
Purchase of Investments		 -120 -138 -237 -207 -111 -149 -128 -94 -86 -32 -61
Sale and/or Maturity of Investments		 184 116 185 244 101 182 136 115 115 84 115
Net Cash From Financing Activities		 0.26 0.41 0.30 0.13 0.08 0.12 0.02 2.75 -1.54 -0.90 0.55
Net Cash From Continuing Financing Activities		 0.26 0.41 0.30 0.13 0.08 0.12 0.02 2.75 -1.54 -0.90 0.55
Repayment of Debt		 - - - - - - 0.00 - -3.21 -7.63 -0.53
Other Financing Activities, net		 0.26 0.31 0.30 - 0.08 - 0.02 1.93 1.67 0.84 1.08
Effect of Exchange Rate Changes		 - - - - - - 0.00 - -0.74 1.12 0.15

Annual Balance Sheets for Nuvation Bio

This table presents Nuvation Bio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 222 776 672 621 541
Total Current Assets		 221 772 667 616 526
Cash & Equivalents		 30 132 101 43 36
Short-Term Investments		 187 636 562 572 467
Accounts Receivable		 - - - 0.00 13
Inventories, net		 - - - - 0.00
Prepaid Expenses		 0.91 3.64 3.82 1.52 7.27
Plant, Property, & Equipment, net		 0.69 0.79 0.89 0.72 0.59
Total Noncurrent Assets		 0.42 3.29 3.93 4.33 14
Intangible Assets		 - - - 0.00 4.62
Other Noncurrent Operating Assets		 0.42 3.29 3.93 4.33 9.16
Total Liabilities & Shareholders' Equity		 222 776 672 621 541
Total Liabilities		 6.71 30 17 16 77
Total Current Liabilities		 6.55 17 13 14 58
Short-Term Debt		 - - - 0.00 6.28
Accounts Payable		 2.17 3.93 2.14 2.21 6.35
Accrued Expenses		 4.38 12 9.82 9.79 33
Current Deferred Revenue		 - - - 0.00 11
Other Current Liabilities		 - 0.86 1.21 1.97 1.66
Total Noncurrent Liabilities		 0.16 13 3.90 2.39 19
Noncurrent Deferred Revenue		 0.16 - - 0.00 16
Other Noncurrent Operating Liabilities		 0.00 13 3.90 2.39 3.02
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 215 746 655 605 464
Total Preferred & Common Equity		 215 746 655 605 464
Total Common Equity		 215 746 655 605 464
Common Stock		 289 910 928 948 1,374
Retained Earnings		 -76 -163 -267 -343 -911
Accumulated Other Comprehensive Income / (Loss)		 1.56 -1.19 -5.53 0.18 0.57

Quarterly Balance Sheets for Nuvation Bio

This table presents Nuvation Bio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 686 657 641 631 613 595 572 492
Total Current Assets		 681 653 637 625 608 587 565 476
Cash & Equivalents		 139 30 50 24 35 34 30 48
Short-Term Investments		 538 619 584 598 567 547 519 419
Accounts Receivable		 - - - - - 0.12 0.11 0.41
Inventories, net		 - - - - - - - 0.01
Prepaid Expenses		 5.09 3.68 3.53 2.98 6.80 5.99 12 8.42
Plant, Property, & Equipment, net		 0.90 0.84 0.80 0.76 0.69 0.75 0.72 0.56
Total Noncurrent Assets		 4.20 3.66 3.38 4.76 4.38 6.87 5.73 16
Intangible Assets		 - - - - - 2.93 2.78 4.41
Other Noncurrent Operating Assets		 4.20 3.66 3.38 4.76 4.38 3.94 2.95 12
Total Liabilities & Shareholders' Equity		 686 657 641 631 613 595 572 492
Total Liabilities		 19 16 17 19 19 63 69 73
Total Current Liabilities		 14 13 13 16 16 51 59 53
Short-Term Debt		 - - - - - 12 8.43 5.69
Accounts Payable		 3.00 2.95 2.58 2.37 2.44 5.21 12 11
Accrued Expenses		 9.92 8.36 9.55 12 11 20 24 24
Current Deferred Revenue		 - - - - - 12 13 11
Other Current Liabilities		 1.10 1.24 1.28 1.92 2.02 2.08 1.78 1.89
Total Noncurrent Liabilities		 4.54 3.44 3.37 3.14 3.32 12 9.83 20
Noncurrent Deferred Revenue		 - - - - - 9.16 7.94 14
Other Noncurrent Operating Liabilities		 4.54 3.44 3.37 3.14 3.32 2.41 1.89 6.64
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 668 641 625 612 594 532 503 419
Total Preferred & Common Equity		 668 641 625 612 594 257 503 419
Total Common Equity		 668 641 625 612 594 257 503 419
Common Stock		 922 933 938 944 953 1,079 1,363 1,383
Retained Earnings		 -246 -289 -309 -329 -358 -820 -861 -964
Accumulated Other Comprehensive Income / (Loss)		 -8.12 -2.94 -4.40 -3.30 -1.17 -1.27 1.38 0.55

Annual Metrics And Ratios for Nuvation Bio

This table displays calculated financial ratios and metrics derived from Nuvation Bio's official financial filings.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -94.32% -25.42% -5.22% -437.74%
EBIT Growth		 0.00% -104.76% -23.06% 9.19% -492.91%
NOPAT Growth		 0.00% -114.27% -28.31% 16.63% -493.68%
Net Income Growth		 0.00% -108.47% -19.98% 27.25% -649.24%
EPS Growth		 0.00% -2.33% -9.09% 27.08% -502.86%
Operating Cash Flow Growth		 0.00% -86.67% -40.94% 29.25% -91.79%
Free Cash Flow Firm Growth		 0.00% 0.00% -119.10% 29.97% -467.02%
Invested Capital Growth		 0.00% -1,174.66% 62.45% -16.27% -269.56%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 264.15%
EBITDA Q/Q Growth		 0.00% -6.93% -0.34% 0.50% -5.78%
EBIT Q/Q Growth		 0.00% -12.71% 1.48% 3.26% -6.20%
NOPAT Q/Q Growth		 0.00% -20.53% 4.22% 3.39% -5.92%
Net Income Q/Q Growth		 0.00% -15.81% 3.95% 8.52% -6.70%
EPS Q/Q Growth		 0.00% -2.33% 4.00% 7.89% 3.21%
Operating Cash Flow Q/Q Growth		 0.00% -18.29% 7.07% 1.65% -31.54%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 5.37% 2.00% -7.85%
Invested Capital Q/Q Growth		 0.00% 7.42% -0.75% 9.19% 14.40%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 10.10%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -7,657.26%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -7,527.33%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -7,551.62%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -7,213.76%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 95.06% 96.79% 94.37% 75.59% 95.53%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -19.37% -18.07% -14.87% -12.03% -106.27%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -102.32%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -97.74%
Return on Common Equity (ROCE)		 -19.37% -18.07% -14.87% -12.03% -106.27%
Return on Equity Simple (ROE_SIMPLE)		 -19.37% -11.64% -15.91% -12.53% -122.46%
Net Operating Profit after Tax (NOPAT)		 -30 -65 -84 -70 -415
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -5,269.13%
Net Nonoperating Expense Percent (NNEP)		 -5.15% -4.37% -2.85% -0.93% -27.46%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -11.55% -88.25%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 89.90%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 879.37%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 6,658.06%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 7,537.43%
Earnings before Interest and Taxes (EBIT)		 -44 -90 -110 -100 -595
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -44 -85 -107 -112 -603
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 1.00 2.48 0.64 0.55 1.93
Price to Tangible Book Value (P/TBV)		 1.00 2.48 0.64 0.55 1.95
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 113.71
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 50.21
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.01
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -1.03 -1.02 -1.01 -1.04
Leverage Ratio		 1.03 1.04 1.03 1.03 1.09
Compound Leverage Factor		 0.98 1.01 0.98 0.78 1.04
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 1.34%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 1.34%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 98.66%
Debt to EBITDA		 0.00 0.00 0.00 0.00 -0.01
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.83
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 -0.02
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 1.21
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 19.34 37.33 14.81 11.98 2.06
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 33.69 45.62 50.70 44.11 9.04
Quick Ratio		 33.10 45.40 50.41 44.00 8.91
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -45 -98 -69 -388
Operating Cash Flow to CapEx		 -25,192.41% -24,180.85% -26,921.01% -123,634.55% -80,501.85%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -1,139.12
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 -382.44
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -382.92
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.01
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 12.08
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 1.65
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 220.63
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 -220.63
Capital & Investment Metrics		 - - - - -
Invested Capital		 -1.76 -22 -8.42 -9.79 -36
Invested Capital Turnover		 0.00 0.00 0.00 0.00 -0.34
Increase / (Decrease) in Invested Capital		 0.00 -21 14 -1.37 -26
Enterprise Value (EV)		 -0.91 1,083 -244 -284 395
Market Capitalization		 216 1,851 419 331 895
Book Value per Share		 $11.65 $3.43 $3.00 $2.76 $1.38
Tangible Book Value per Share		 $11.65 $3.43 $3.00 $2.76 $1.36
Total Capital		 215 746 655 605 470
Total Debt		 0.00 0.00 0.00 0.00 6.28
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00
Net Debt		 -217 -768 -663 -615 -500
Capital Expenditures (CapEx)		 0.15 0.28 0.36 0.06 0.16
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.71 -13 -9.34 -12 -32
Debt-free Net Working Capital (DFNWC)		 214 755 654 602 474
Net Working Capital (NWC)		 214 755 654 602 468
Net Nonoperating Expense (NNE)		 11 22 20 5.93 153
Net Nonoperating Obligations (NNO)		 -217 -768 -663 -615 -500
Total Depreciation and Amortization (D&A)		 0.10 4.78 3.87 -12 -8.32
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -406.05%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 6,024.31%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 5,944.51%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.44) ($0.48) ($0.35) ($2.11)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 219.06M 216.72M 218.88M 268.77M
Adjusted Diluted Earnings per Share		 $0.00 ($0.44) ($0.48) ($0.35) ($2.11)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 219.06M 216.72M 218.88M 268.77M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.44) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 219.06M 218.80M 219.05M 338.68M
Normalized Net Operating Profit after Tax (NOPAT)		 -30 -65 -84 -70 -415
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -5,269.13%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -7,213.76%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 -1,743.52
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -1,216.54
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -1,743.99
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -1,217.01
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Nuvation Bio

This table displays calculated financial ratios and metrics derived from Nuvation Bio's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -32.45% -1.50% -41.94% 10.32% -3.75% 2.27% 13.99% -1,482.40% -68.29% -136.91% -141.73%
EBIT Growth		 -27.60% 6.42% -20.75% 23.93% 10.14% 13.96% 17.61% -1,662.31% -82.57% -166.43% -166.87%
NOPAT Growth		 -28.73% 17.82% 5.93% 31.00% 10.22% 14.40% 23.84% -1,700.10% -82.62% -158.95% -192.11%
Net Income Growth		 -23.77% 17.06% -2.03% 40.79% 27.77% 33.86% 31.92% -2,140.76% -109.73% -258.63% -259.90%
EPS Growth		 -9.09% 16.67% 0.00% 43.75% 25.00% 30.00% 30.00% -2,000.00% -66.67% 0.00% -128.57%
Operating Cash Flow Growth		 -113.66% 31.14% 22.46% 35.04% 42.49% 7.05% 18.77% -113.46% -92.42% -208.08% -171.48%
Free Cash Flow Firm Growth		 -124.04% -59,259.08% -21.81% 31.04% 56.02% 57.44% 46.21% -1,231.14% 86.41% 14.01% 52.92%
Invested Capital Growth		 65.50% 62.45% 53.05% 32.29% -29.00% -16.27% 7.58% -311.55% -292.05% -269.56% -476.20%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -49.34% 685.56% -46.00%
EBITDA Q/Q Growth		 14.24% 13.60% -16.59% -3.80% 0.78% 18.61% -2.61% -1,809.78% 89.45% -14.58% -4.69%
EBIT Q/Q Growth		 16.76% 16.82% -9.78% -0.07% 1.66% 20.36% -5.13% -2,040.45% 89.81% -16.22% -5.30%
NOPAT Q/Q Growth		 22.53% 17.06% -8.99% 1.47% -0.80% 20.91% 3.03% -2,228.75% 89.77% -12.14% -9.38%
Net Income Q/Q Growth		 21.96% 23.37% -4.23% 5.00% 4.80% 29.83% -7.29% -3,026.64% 91.09% -19.98% -7.67%
EPS Q/Q Growth		 25.00% 16.67% 0.00% 10.00% 0.00% 22.22% 0.00% -2,600.00% 92.06% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -4.36% 42.44% -19.55% 9.54% 7.61% 6.97% -4.48% -137.70% 16.72% -48.95% 7.94%
Free Cash Flow Firm Q/Q Growth		 -11.03% 14.73% 11.78% 17.43% 29.19% 17.50% -11.50% -1,943.50% 99.28% -422.20% 38.95%
Invested Capital Q/Q Growth		 37.55% -0.75% 7.29% -16.06% -18.99% 9.19% 26.30% -416.82% -13.35% 14.40% -14.90%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.13% -108.39% 26.18% 32.10%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -32,852.26% -6,842.50% -998.00% -1,934.82%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -32,779.44% -6,616.37% -944.53% -1,913.23%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -32,700.35% -6,575.65% -972.88% -1,897.08%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -32,229.41% -5,668.50% -865.79% -1,726.20%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 93.36% 86.00% 81.65% 77.52% 75.04% 66.11% 67.47% 98.56% 86.20% 88.99% 90.99%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -12.67% -14.87% -15.33% -13.72% -12.95% -12.03% -11.15% -88.30% -95.54% -106.27% -119.66%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -75.92% -23.65% -13.18% -37.60%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -74.82% -20.38% -11.73% -34.21%
Return on Common Equity (ROCE)		 -12.67% -14.87% -15.33% -13.72% -12.95% -12.03% -11.15% -67.31% -95.54% -106.27% -119.66%
Return on Equity Simple (ROE_SIMPLE)		 -16.24% 0.00% -16.32% -14.47% -13.55% 0.00% -11.59% -198.57% -105.88% 0.00% -144.56%
Net Operating Profit after Tax (NOPAT)		 -21 -17 -19 -18 -18 -15 -14 -329 -34 -38 -41
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -22,945.61% -4,631.46% -661.17% -1,339.26%
Net Nonoperating Expense Percent (NNEP)		 -0.76% -0.53% -0.46% -0.35% -0.19% 0.12% -0.10% -22.15% -1.29% -2.10% -2.25%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -2.41% - - - -8.03% -9.72%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 93.87% 208.39% 73.82% 67.90%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,143.07% 2,693.54% 453.35% 1,147.63%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 31,659.72% 3,814.44% 513.03% 797.70%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 32,802.79% 6,507.98% 966.38% 1,945.33%
Earnings before Interest and Taxes (EBIT)		 -29 -24 -27 -27 -26 -21 -22 -469 -48 -56 -59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -28 -25 -29 -30 -30 -24 -25 -471 -50 -57 -60
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.73 0.64 0.57 0.63 0.48 0.55 1.34 2.81 1.14 1.93 1.42
Price to Tangible Book Value (P/TBV)		 0.73 0.64 0.57 0.63 0.48 0.55 1.34 2.84 1.14 1.95 1.44
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 502.95 264.00 113.71 54.40
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 297.73 13.90 50.21 12.32
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.02 0.01 0.01
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.02 -1.02 -1.02 -1.02 -1.01 -1.01 -1.04 -1.05 -1.04 -1.05
Leverage Ratio		 0.87 1.03 1.03 1.03 1.03 1.03 1.03 1.07 1.08 1.09 1.09
Compound Leverage Factor		 0.81 0.89 0.84 0.80 0.77 0.68 0.69 1.05 0.93 0.97 0.99
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.14% 1.65% 1.34% 1.34%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.14% 1.65% 1.34% 1.34%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 50.56% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 47.30% 98.35% 98.66% 98.66%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 -0.01 -0.01 -0.01
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.04 0.95 0.83 0.72
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.03 -0.02 -0.02 -0.01
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.51 1.38 1.21 1.04
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 16.33 15.24 14.05 14.44 9.42 12.40 25.29 3.46 3.65 5.35 2.82
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 23.77% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 48.63 50.70 51.99 47.51 38.74 44.11 38.58 11.49 9.57 9.04 9.01
Quick Ratio		 48.27 50.41 51.70 47.24 38.55 44.00 38.15 11.37 9.30 8.91 8.85
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -36 -31 -27 -23 -16 -13 -15 -301 -2.18 -11 -6.94
Operating Cash Flow to CapEx		 -27,273.79% -27,405.08% -161,083.33% -79,477.27% -73,431.82% -115,607.69% -58,155.56% 0.00% -21,003.38% 0.00% -59,204.17%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2,280.56 -18.13 0.00 -128.44
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -282.76 -259.04 0.00 -789.39
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -282.76 -260.28 0.00 -790.72
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.02
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.85 2.92 12.08 17.56
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.35 0.39 1.65 1.41
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,055.17 940.75 220.63 258.13
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,055.17 -940.75 -220.63 -258.13
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -8.36 -8.42 -7.81 -9.06 -11 -9.79 -7.22 -37 -42 -36 -42
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.06 -0.08 -0.34 -0.45
Increase / (Decrease) in Invested Capital		 16 14 8.82 4.32 -2.42 -1.37 0.59 -28 -31 -26 -34
Enterprise Value (EV)		 -187 -244 -286 -240 -329 -284 196 427 30 395 135
Market Capitalization		 489 419 363 394 293 331 797 722 571 895 596
Book Value per Share		 $3.06 $3.00 $2.93 $2.85 $2.79 $2.76 $2.71 $1.04 $2.02 $1.38 $1.24
Tangible Book Value per Share		 $3.06 $3.00 $2.93 $2.85 $2.79 $2.76 $2.71 $1.03 $2.01 $1.36 $1.23
Total Capital		 668 655 641 625 612 605 594 544 511 470 425
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 12 8.43 6.28 5.69
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -676 -663 -649 -634 -622 -615 -601 -569 -541 -500 -461
Capital Expenditures (CapEx)		 0.10 0.06 0.01 0.02 0.02 0.01 0.03 0.00 0.15 -0.01 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.92 -9.34 -8.87 -9.88 -13 -12 -8.97 -33 -35 -32 -38
Debt-free Net Working Capital (DFNWC)		 667 654 640 624 609 602 592 548 514 474 428
Net Working Capital (NWC)		 667 654 640 624 609 602 592 536 506 468 423
Net Nonoperating Expense (NNE)		 6.67 3.81 3.16 2.35 1.21 -0.79 0.65 133 7.54 12 12
Net Nonoperating Obligations (NNO)		 -676 -663 -649 -634 -622 -615 -601 -569 -545 -500 -461
Total Depreciation and Amortization (D&A)		 0.65 -0.38 -2.09 -3.17 -3.38 -3.20 -2.76 -2.18 -1.94 -1.44 -1.16
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,324.25% -1,607.72% -406.05% -349.08%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 38,168.01% 23,791.67% 6,024.31% 3,910.56%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 37,357.28% 23,401.94% 5,944.51% 3,858.67%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.12) ($0.10) ($0.10) ($0.09) ($0.09) ($0.07) ($0.07) ($1.89) ($0.15) $0.00 ($0.16)
Adjusted Weighted Average Basic Shares Outstanding		 218.30M 216.72M 218.74M 218.85M 218.94M 218.88M 219.05M 244.74M 273.57M 268.77M 338.61M
Adjusted Diluted Earnings per Share		 ($0.12) ($0.10) ($0.10) ($0.09) ($0.09) ($0.07) ($0.07) ($1.89) ($0.15) $0.00 ($0.16)
Adjusted Weighted Average Diluted Shares Outstanding		 218.30M 216.72M 218.74M 218.85M 218.94M 218.88M 219.05M 244.74M 273.57M 268.77M 338.61M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 218.39M 218.80M 218.80M 218.94M 218.94M 219.05M 247.17M 249.25M 336.57M 338.68M 340.26M
Normalized Net Operating Profit after Tax (NOPAT)		 -21 -17 -19 -18 -18 -15 -14 -329 -34 -38 -41
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -22,945.61% -4,631.46% -661.17% -1,339.26%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -32,229.41% -5,668.50% -865.79% -1,726.20%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3,554.92 -398.38 0.00 -1,083.44
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2,494.47 -280.59 0.00 -764.87
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3,554.92 -399.61 0.00 -1,084.78
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2,494.47 -281.82 0.00 -766.20
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

Nuvation Bio began recognizing operating revenue in Q1 2025, marking an early milestone in its commercialization efforts. Despite this progress, the company continues to invest heavily in R&D and SG&A, resulting in widening losses and negative operating cash flow. Its strong cash and investment position, combined with minimal debt, supports its runway as it advances its pipeline.

  • Q1 2025 revenue of $3.08 M versus $0 in Q1 2024 indicates the company’s first commercial sales.
  • Robust liquidity with $47.98 M in cash & equivalents plus $418.75 M in short-term investments at quarter end.
  • Gross margin improved to 32.1% in Q1 2025, reflecting product revenues outpacing cost of goods sold.
  • Current ratio of approximately 9.0, underlining strong short-term liquidity.
  • Minimal leverage, with total debt just 1.4% of total capital and a net debt position that remains negative.
  • Q1 2025 net loss widened to $53.2 M from $14.8 M in Q1 2024, driven by higher operating expenses.
  • Operating cash flow remained deeply negative at -$42.6 M in Q1 2025, indicating ongoing burn.
  • Total operating expenses of $59.99 M, including $24.60 M in R&D and $35.39 M in SG&A, continue to outpace revenues.
  • Assets declined from $613 M in Q1 2024 to $492 M in Q1 2025 as cash and investments funded operations.
07/13/25 02:45 AMAI Generated. May Contain Errors.

Frequently Asked Questions About Nuvation Bio's Financials

When does Nuvation Bio's financial year end?

According to the most recent income statement we have on file, Nuvation Bio's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Nuvation Bio's net income changed over the last 4 years?

Nuvation Bio's net income appears to be on an upward trend, with a most recent value of -$567.94 million in 2024, rising from -$41.66 million in 2020. The previous period was -$75.80 million in 2023. Check out Nuvation Bio's forecast to explore projected trends and price targets.

What is Nuvation Bio's operating income?
Nuvation Bio's total operating income in 2024 was -$592.63 million, based on the following breakdown:
  • Total Gross Profit: $795 thousand
  • Total Operating Expenses: $593.42 million
How has Nuvation Bio's revenue changed over the last 4 years?

Over the last 4 years, Nuvation Bio's total revenue changed from $0.00 in 2020 to $7.87 million in 2024, a change of 787,300,000.0%.

How much debt does Nuvation Bio have?

Nuvation Bio's total liabilities were at $76.84 million at the end of 2024, a 369.6% increase from 2023, and a 1,045.5% increase since 2020.

How much cash does Nuvation Bio have?

In the past 4 years, Nuvation Bio's cash and equivalents has ranged from $29.76 million in 2020 to $132.42 million in 2021, and is currently $35.72 million as of their latest financial filing in 2024.

How has Nuvation Bio's book value per share changed over the last 4 years?

Over the last 4 years, Nuvation Bio's book value per share changed from 11.65 in 2020 to 1.38 in 2024, a change of -88.2%.


Related Companies

This page (NYSE:NUVB) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...
Paradigm Press | Sponsored
[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...
Golden Portfolio | Sponsored
Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Banks aren’t ready for this altcoin—are you?
Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...
Crypto 101 Media | Sponsored